Showing results (151-160 of 366) with videos related to
Sort By:
Pageof 37
Breast Cancer Research and Treatment|June 11, 2008
No evidence that CDKN1B (p27) polymorphisms modify breast cancer risk in BRCA1 and BRCA2 mutation carriersAmanda B Spurdle, Andrew J Deans, David Duffy, et al.Nature Communications|June 8, 2023
Identification of BRCA1/2 mutation female carriers using circulating microRNA profilesKevin Elias, Urszula Smyczynska, Konrad Stawiski, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 6, 2019
Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safetyRebecca S Kristeleit, Ana Oaknin, Isabelle Ray-Coquard, et al.Clinical Genetics|September 12, 2022
Fanconi anemia caused by biallelic inactivation of BRCA2 can present with an atypical cancer phenotype in adulthoodKara N Maxwell, Vishal Patel, Kevin T Nead, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 5, 2014
Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutationBella Kaufman, Ronnie Shapira-Frommer, Rita K Schmutzler, et al.BJOG : an International Journal of Obstetrics and Gynaecology|July 23, 2025
What Happens After Menopause (WHAM)? A Progress Report of a Prospective Controlled Study of Women After Pre-Menopausal Risk-Reducing Bilateral Salpingo-OophorectomySarah A L Price, Pauline M Maki, Samar R El Khoudary, et al.American Journal of Medical Genetics. Part A|May 13, 2025
Parental Communication with their Children about Cancer Risk and DTC Cascade Genetic Testing: Implications for Genetic Education and CounselingMarcelo M Sleiman, Talia Zamir, Beth N Peshkin, et al.Future Oncology (London, England)|October 15, 2016
A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationaleSteven J Isakoff, Shannon Puhalla, Susan M Domchek, et al.JCO Precision Oncology|July 29, 2021
Comprehensive Breast Cancer Risk Assessment for CHEK2 and ATM Pathogenic Variant Carriers Incorporating a Polygenic Risk Score and the Tyrer-Cuzick ModelShannon Gallagher, Elisha Hughes, Allison W Kurian, et al.Breast Cancer Research and Treatment|April 23, 2010
Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomyLori J Pierce, Kelly-Anne Phillips, Kent A Griffith, et al.Pageof 37